Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid pain control in Ixekizumab targeted axial spondyloarthritis
2023-508976-12-00Phase 4Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of ixekizumab in axial spondyloarthritis (axSpA), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Change in fMRI BOLD signal voxel count during initial treatment with ixekizumab vs pre-treatment. Started Jan 2024; status: completed.
02
Drugs
ixekizumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2023-508976-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508976-12-00.